Claims
- 1. A method for protecting against cataract development in a subject, during a vitreous replacement, comprising use of a vitreous replacement solution having a low oxygen concentration.
- 2. The method of claim 1, wherein the oxygen concentration of the low-oxygen-concentration solution is between about 0% and about 2%.
- 3. The method of claim 2, wherein the oxygen concentration is about 0%.
- 4. The method of claim 1, wherein the low-oxygen-concentration solution includes reduced glutathione and ascorbic acid.
- 5. The method of claim 1, wherein the low-oxygen-concentration solution includes reduced glutathione.
- 6. The method of claim 5, wherein the glutathione in the solution has a concentration between about 0.01 mM and about 10 mM.
- 7. The method of claim 6, wherein the glutathione concentration is between about 0.1 mM and about 2 mM.
- 8. The method of claim 7, wherein the glutathione concentration is about 1 mM.
- 9. The method of claim 1, wherein the low-oxygen-concentration solution is an initial vitreous replacement solution from which at least a portion of the oxygen has been removed.
- 10. The method of claim 9, wherein the at least a portion of the oxygen is removed by subjecting the initial solution to at least a partial vacuum.
- 11. The method of claim 10, wherein the initial solution is subjected to the at least a partial vacuum for about 10 minutes to about 15 minutes.
- 12. The method of claim 9, wherein the at least a portion of the oxygen is removed by introducing an essentially-oxygen-free gas into the initial solution.
- 13. The method of claim 12, wherein the essentially-oxygen-free gas is an inert gas.
- 14. The method of claim 12, wherein the essentially-oxygen-free gas is a noble gas.
- 15. The method of claim 12, wherein the essentially-oxygen-free gas is nitrogen gas.
- 16. The method of claim 12, wherein the essentially-oxygen-free gas is introduced into the initial solution by bubbling the gas through the initial solution, thereby producing a low-oxygen-concentration solution.
- 17. The method of claim 16, wherein the gas is bubbled through the initial solution for about 10 minutes immediately prior to introduction of the low-oxygen-concentration solution into an eye of a subject.
- 18. The method of claim 1, wherein the low-oxygen-concentration solution includes ascorbic acid.
- 19. The method of claim 18, wherein the ascorbic acid in the solution has a concentration that is sufficiently high to protect against cataract development in a subject.
- 20. The method of claim 18, wherein the ascorbic acid concentration is between about 0 mM and about 10 mM.
- 21. The method of claim 20, wherein the ascorbic acid concentration is between about 0.5 mM and about 5 mM.
- 22. The method of claim 21, wherein the ascorbic acid concentration is between about 1 mM and about 3 mM.
- 23. The method of claim 22, wherein the ascorbic acid concentration is about 2 mM.
- 24. Use of a vitreous replacement solution having a low-oxygen concentration during a vitrectomy, wherein the low-oxygen-concentration solution is produced by removing at least a portion of the oxygen from an initial vitreous replacement solution.
- 25. The use recited in claim 24, wherein the low-oxygen-concentration solution includes reduced glutathione.
- 26. A low-oxygen-concentration vitreous replacement solution for use in vitrectomies, wherein the low-oxygen-concentration solution is an initial vitreous replacement solution from which at least a portion of the oxygen has been removed.
- 27. The low-oxygen-concentration solution of claim 26, which includes reduced glutathione.
- 28. The low-oxygen-concentration solution of claim 26, which includes ascorbic acid.
- 29. The low-oxygen-concentration solution of claim 26, which includes reduced glutathione and ascorbic acid.
- 30. A method for protecting against cataract development and/or for treating a cataract in a subject, comprising reducing oxygen concentration in a vitreous of the subject.
RELATED APPLICATION
[0001] This application claims the benefit of U.S. Provisional Application No. 60/406,907, filed Aug. 28, 2002.
STATEMENT OF GOVERNMENT INTEREST
[0002] This invention was made with government support under NIH Grant No. R01 EY02283. As such, the United States government has certain rights in this invention.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60406907 |
Aug 2002 |
US |